| Literature DB >> 26712785 |
Ningjian Liang1, David D Kitts2.
Abstract
Chlorogenic acids (CGAs) are esters formed between caffeic and quinic acids, and represent an abundant group of plant polyphenols present in the human diet. CGAs have different subgroups that include caffeoylquinic, p-coumaroylquinic, and feruloyquinic acids. Results of epidemiological studies suggest that the consumption of beverages such as coffee, tea, wine, different herbal infusions, and also some fruit juices is linked to reduced risks of developing different chronic diseases. These beverages contain CGAs present in different concentrations and isomeric mixtures. The underlying mechanism(s) for specific health benefits attributed to CGAs involves mitigating oxidative stress, and hence the related adverse effects associated with an unbalanced intracellular redox state. There is also evidence to show that CGAs exhibit anti-inflammatory activities by modulating a number of important metabolic pathways. This review will focus on three specific aspects of the relevance of CGAs in coffee beverages; namely: (1) the relative composition of different CGA isomers present in coffee beverages; (2) analysis of in vitro and in vivo evidence that CGAs and individual isomers can mitigate oxidative and inflammatory stresses; and (3) description of the molecular mechanisms that have a key role in the cell signaling activity that underlines important functions.Entities:
Keywords: anti-inflammation; antioxidant activity; chlorogenic acid isomers; coffee; inflammatory stress; oxidative stress
Mesh:
Substances:
Year: 2015 PMID: 26712785 PMCID: PMC4728630 DOI: 10.3390/nu8010016
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Chemical structures of 3-CQA, 4-CQA, 5-CQA, 3,4-diCQA, 3,5-diCQA, 4,5-diCQA, 3-FQA, 4-FQA, 5-FQA, 3-p-CoQA, 4-p-CoQA, and 5-p-CoQA.
Figure 2Absorption of CGA when passing through human digestive tract.
The antioxidant activity of CGA isomers evaluated by chemical assays.
| Chemical Assays | End-Point Measure | CGA Isomer | Concentration/Exposure Time | Results | References |
|---|---|---|---|---|---|
| DPPH assay | DPPH | 5-CQA | 5–80 μM for 3 h | 10%~90% inhibition on DPPH | [ |
| Xanthine/xanthine oxidase system | DMPO/·OOH adducts | 5-CQA | 20 μM for 2.5 min | ↓ 30% ·OOH | [ |
| FeSO4 + H2O2 | DMPO/·OH adducts | 5-CQA | 20 μM for 2.5 min | ↓ 51% ·OH | [ |
| FeSO4 + H2O2 | DMPO/·OH adducts | 5-CQA | 100–400 μM for 1 min | ↓ 50% to 80% ·OH | [ |
| ABTS assay | ABTS·+ | 5-CQA | Serials concentration for 15 min | The ability of 100 g of CGA in scavenging ABTS·+ is equivalent to 3.7 mmol Trolox | [ |
| Rat brain homogenates + sodium nitroprusside | MDA | 5-CQA | 1.56–6.25 μg/mL | No significant inhibition of MDA | [ |
| Liposome system containing AAPH | MDA | 5-CQA | 0.1–0.5 mM | Second order rate of constant of the reactions of LOO· with CGA is 1.28 ± 0.11 × 105 M−1·s−1 | [ |
| Pulse radiolysis to generate O2- | O2- | 5-CQA | 0.2–0.75 mM | Second order rate of constant of the reactions of O2- with CGA is 0.96 ± 0.01 × 106 M−1·s−1 | [ |
| Fenton-type reaction to generate ·OH | ·OH | 5-CQA | 0.1–0.75 mM | Second order rate of constant of the reactions of ·OH with CGA is 3.34 ± 0.19 × 109 M−1·s−1 | [ |
| Potassium phosphate to generate ONOO- | ONOO- | 5-CQA | 80 μM | Second order rate of constant of the reactions of ONOO- with CGA is 1.6 ± 0.7 × 105 M−1·s−1 | [ |
| DPPH assay | DPPH | 3-CQA, | 5 μg/mL–60 μg/mL | EC50 a 3-CQA:13.4 μg/mL | [ |
| 4-CQA, | 4-CQA: 13.2 μg/mL | ||||
| 5-CQA, | 5-CQA: 13.8 μg/mL | ||||
| 3,5-diCQA, | 3,5-diCQA: 9.3 μg/mL | ||||
| 3,4-diCQA, | 3,4-diCQA: 9.4 μg/mL | ||||
| 4,5-diCQA | 4,5-diCQA: 7.5 μg/mL | ||||
| ABTS assay | ABTS·+ | 3-CQA | 50 μg/mL–150 μg/mL | EC50 a 3-CQA: 91.4 μg/mL | [ |
| 4-CQA, | 4-CQA: 87.5 μg/mL | ||||
| 5-CQA, | 5-CQA: 91.5 μg/mL | ||||
| 3,5-diCQA, | 3,5-diCQA: 77.6 μg/mL | ||||
| 3,4-diCQA, | 3,4-diCQA: 77.4 μg/mL | ||||
| 4,5-diCQA | 4,5-diCQA: 67.3 μg/mL | ||||
| FRAP assay | Reducing power | 3-CQA | 25–125 μg/mL | 4,5-diCQA > 3,5-diCQA > 3,4-diCQA > 5-CQA = 4-CQA = 3-CQA | [ |
| 4-CQA, | |||||
| 5-CQA, | |||||
| 3,5-diCQA, | |||||
| 3,4-diCQA, | |||||
| 4,5-diCQA | |||||
| DNA damage protective effect assay | DNA damage | 3-CQA | 50 μg/mL | ↓ 43.1 to 62.4% DNA damage | [ |
| 4-CQA, | |||||
| 5-CQA, | |||||
| 3,5-diCQA, | 4,5-diCQA > 3,4-diCQA > 3,5-diCQA > 5-CQA > 4-CQA > 3-CQA | ||||
| 3,4-diCQA, | |||||
| 4,5-diCQA | |||||
| Plasmid pUC18 + NH2Cl | Supercoiled DNA, nicked circular DNA and linear duple | 5-CQA | 0.01 mM–1.23 mM | Prevented a stepwise conversion of plasmid DNA form supercoiled DNA, nicked circular DNA and linear duplex DNA | [ |
| LDL + copper | Conjugated dienes | 5-CQA | 0.25–1.0 μM | ↑ lag time of LDL oxidation | [ |
| LDL + metmyoglobin + H2O2 | ROS | 5-CQA | 1 molar ratio to metmyoglobin | Effectively blocked LDL oxidation | [ |
a EC50 represents the concentration of the tested compound that results in half-maximal response.
Summary of studies that evaluated the capacity of CGAs to modulate oxidative stress in cell-based and animal-based models.
| Model | End-Point Measure | CGA Isomer | Concentration/Exposure Time | Results Compared to the Control without CGA Treatment | References | |
|---|---|---|---|---|---|---|
| HaCaT cell + H2O2 | H2O2 | 5-CQA | 20 μM for 20 h | ↓ ROS | [ | |
| HaCaT cell + UVB | ROS, DNA damage, cell viability | 5-CQA | 20 μM for 20 h | ↓ ROS | [ | |
| ↓ DNA damage | ||||||
| ↑ 13% cell viability | ||||||
| Mesenchymal stem cell + H2O2 | Chromosomal condensation, cell apoptosis, ROS | 5-CQA | 10 mM for 12 h | ↓ Chromosomal condensation | [ | |
| ↓ Cell apoptosis | ||||||
| ↓ ROS | ||||||
| Primary cortical neurons + H2O2 | NADPH: quinine oxido-reductase 1, Cell viability | 5-CQA | 12.5–100 μM for 1 h | ↑ NADPH: quinine oxido-reductase 1 | [ | |
| ↑ Cell viability | ||||||
| Differentiated neuronal PC12 cells + H2O2 | Cell viability, GSH | 5-CQA | 6.2–25 μM for 2 h | ↑ Cell viability | [ | |
| Attenuated GSH decrease | ||||||
| Differentiated neuronal PC12 cells + FeSO4 | Cell viability, ROS, MDA | 5-CQA | 6.2–25 μM for 2 h | Did not change cell viability | [ | |
| ↓ ROS level | ||||||
| ↓ MDA | ||||||
| Differentiated neuronal PC12 cell + | Cell viability, GSH | 5-CQA | 6.2–25 μM for 2 h | ↑ Cell viability | [ | |
| Did not change GSH level | ||||||
| Human breast cancer cell line MCF-7+ | Global methylation status | 5-CQA | 1–20 μM for 8 days | ↓ Global methylation | [ | |
| Human breast cancer cell line MDA-MB-231+ | Global methylation status | 5-CQA | 0.2–20 μM for 3 days | Did not change the global methylation status | [ | |
| Human breast cancer cell line T-47D+ | Global methylation status | 5-CQA | 20–50 μM for 2 days | ↓ Global methylation | [ | |
| Human lymphocyte + X-ray radiation | Genetic damage index | 5-CQA | 0.5–4 μg/mL | ↓ Genetic damge index by 4.49% to 48.15% | [ | |
| Mouse epidermal cell line JB6 + UVB | GST, NADPH: quinone oxido-reductase, Nrf2 | 5-CQA | 5–160 μM for 1 h | ↑ GST | [ | |
| ↑ NADPH:quinone oxido-reductase | ||||||
| ↑ Nrf2 nuclear translocation | ||||||
| Differentiated neuronal PC12 cell + H2O2 | Mitochondrial membrane depolarization | 3-CQA, 4-CQA, 5-CQA | 10 μM for 20 min | Protected mitochondrial membrane depolarization through | [ | |
| ↓ Caspase 9 activation | ||||||
| Human hepatoma HepG2 cell + | ROS, GSH, GPx, GR, MDA | 5-CQA, 3,5-diCQA | 10–20 μM for 20 h | ↓ ROS, ↑ GSH, ↑ GR, ↓ GPx, ↓ MDA | [ | |
| Type 2 diabetic rat model | Lipid peroxidation, GSH, VC, VE | 5-CQA | Oral administration at 5 mg/kg body weight daily for 45 days | ↓ Plasma lipid hydroperoxides, ↑ GSH, ↑ VC, ↑ VE | [ | |
| Type 2 diabetic rat model | Lipid peroxidation, GST, SOD, GPx, CAT | 5-CQA | Oral administration at 5 mg/kg body weight daily for 45 days | ↓ Lipid oxidation, ↑ GST, ↑ SOD, ↑ GPx, ↑ CAT | [ | |
| Methamphetamine induced oxidative stress rat model | NO, MDA, SOD, GPx | 5-CQA | Oral administration at 60 mg/kg body weight, single dose | ↓ NO, ↓ MDA, ↑ SOD, ↑ GPx | [ | |
| Cd induced brain impairment rat model | SOD, CAT, GPx, GSH, VC, VE, MDA | 5-CQA | Intragastric administration, 60 mg/kg body weight daily for 30 days | ↑ SOD, ↑ CAT, ↑ GPx, ↑ GSH, ↑VC, ↑ VE, ↓ MDA | [ | |
| Scopolamine induced brain impairment rat model | MDA | 5-CQA | Orally administered at 3–9 mg/kg body weight, single dose | ↓ MDA | [ | |
| Benzopyrene induced gastrointestinal pathogenesis rat model | GST, Cytochrome P-450 | 5-CQA | Eating 0.2% 5-CQA containing diet for 10 weeks | ↑ GST, | [ | |
| Did not significantly change cytochrome P-450 | ||||||
| Sodium pentobarbital induced intestinal ischemia-reperfusion rat model | Vascular permeability in the small intestine | 5-CQA | Directly administrate 1 mM into jejunum, single dose | Attenuated the increased vascular permeability | [ | |
| Azoxymethane induced colon cancer mice model | GSH/GSSG ratio | 5-CQA | Orally administered at 0.1% 5-CQA containing diet for 20 weeks | ↑ Hepatic GSH/GSSG ratio | [ | |
| UV irradiation induced erythema formation in Guinea pig and Yucatan micropig | Erythema | 5-CQA | Intradermal delivery of 5-CQA at 1.49 μmol/g skin | Prevented erythema formation induced by UV irradiation | [ | |
| Gamma irradiation induced chromosomal damage in mice model | Frequencies of micro-nucleated polychromatic erythrocytes | 5-CQA | Orally administered at 50–200 mg/kg body weight, single dose | ↓ Frequencies of micro-nucleated polychromatic erythrocytes | [ | |
Summary of studies that evaluated the capacity of CGAs to modulate inflammatory stress in cell-based and animal-based models.
| Models | End-Point Measure | CGA Isomer | Concentration/Exposure Time | Results Compared to the Control without CGA Treatment | References |
|---|---|---|---|---|---|
| Caco-2 + TNF-α and H2O2 | IL-8 | 5-CQA | 0.5–2 mM | ↓ IL-8 | [ |
| Caco-2 + cocktail of inflammatory mediators | IL-6, IL-8 | Mixture of all CGAs | Unknown composition of CGAs for 1 h | ↓ IL-6, ↓ IL-8 | [ |
| RAW 264.7 + LPS | NO, IL-1β, TNF-α, cyclooxygenase-2, NF-κB, IL-6 | 5-CQA | 2–20 μM for 24 h | ↓ NO, ↓ IL-1β, ↓ TNF-α, ↓ IL-6, ↓ cyclooxygenase-2, ↓ NFκB | [ |
| RAW 264.7 + LPS | Cyclooxygenase, Prostaglandin E2, NF-κB | 5-CQA | 12.5–37.4 μg/mL for 2 h | ↓ Cyclooxygenase, ↓ Prostaglandin E2, ↓ NF-κB | [ |
| Trinitrobenzenesulfonic acid induced colitis mice model | Myeloperoxidase, H2O2, NF-κB | 5-CQA | Orally administration at 20 mg/kg body weight, twice a day for 6 days | ↓ Myeloperoxidase, ↓ H2O2, ↓ NF-κB | [ |
| Dextran sulfate sodium induced colitis mice model | IL-1β, TNF-α, macrophage inflammatory protein 2 | 5-CQA | Orally administration at 1 mM for 15 days | ↓ IL-1β, did not significantly change the levels of TNF-α and macrophage inflammatory protein 2 | [ |
| Trinitrobenzenesulfonic acid induced colitis mice model | Myeloperoxidase, H2O2, NF-κB | 5-CQA | Orally administration at 20 mg/kg body weight twice a day | ↓ Myeloperoxidase, ↓ H2O2, ↓ NF-κB | [ |
| Rheumatoid Arthritis rat model | IL-1β, TNF-α, T cells count, Th1 cytokines, Th2 cytokines | 5-CQA | Orally administration at 40 mg/kg body weight | ↓ IL-1β, ↓ TNF-α, ↓ T cells count, ↓ Th1 cytokines, ↑ Th2 cytokines | [ |
| Wounds in diabetic rat | Wound healing speed, NO, MDA, GSH | 5-CQA | Intraperitoneal injection at 50 mg/kg/day for 15 days | ↑ Wound healing speed, ↑ GSH, ↓ NO, ↓ MDA | [ |
| Liver injury rat model | MDA, GSH, TNF-α, NO, cyclooxygenase-2 protein increase | 5-CQA | Orally administration at 2.5–10 mg/kg body weight, twice a day | ↓ MDA, ↑ GSH, ↓ TNF-α, ↓ NO, ↓ cyclooxygenase-2 protein increase | [ |